Seminars in Cancer Biology, Год журнала: 2024, Номер 106-107, С. 179 - 191
Опубликована: Окт. 22, 2024
Язык: Английский
Cell Reports Physical Science, Год журнала: 2024, Номер 5(6), С. 102023 - 102023
Опубликована: Июнь 1, 2024
Dendritic cells (DCs) can form a T cell niche in tumor microenvironment and drive proliferation through immunostimulatory ligands. However, hypoxia severely hinders the infiltration of immune cells, thus restricting cells' anti-tumor response. Microalgae have evolved an efficient photosynthesis system that might be promising oxygen source to mitigate hypoxia. Here, we combine Chlorella vulgaris genetically engineered DC membrane, overexpressing necrosis factor (TNF) ligand proteins OX40L, 4-1BBL, CD70, assemble "photosynthetic micron robot," which generates situ alleviate state microenvironment, thereby improving efficiency immunotherapy. TNF displayed on membrane nanovesicles photosynthetic robot bind their cognate receptors enhance activity effector memory cells. Combined with programmed death-1 antibody, prevents relapse metastasis mouse model.
Язык: Английский
Процитировано
15
RSC Advances, Год журнала: 2024, Номер 14(21), С. 14722 - 14741
Опубликована: Янв. 1, 2024
Manganese-based nanomaterials have seen rapid development in chemodynamic therapy and T 1 -enhanced MRI over the past five years, holding promising prospects various combined applications.
Язык: Английский
Процитировано
10
Acta Biomaterialia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
1
Cancers, Год журнала: 2024, Номер 16(11), С. 2012 - 2012
Опубликована: Май 25, 2024
Triple-negative breast cancer (TNBC), lacking specific receptors found in other subtypes, poses significant treatment challenges due to limited therapeutic options. Therefore, it is necessary develop novel approaches for TNBC. In the last few decades, many attempts have been reported alternative tools TNBC treatment: immunotherapy, radiotherapy, targeted therapy, combination and nanotechnology-based therapy. Among them, therapy show most promise treatment. This review outlines recent advancements these areas, highlighting efficacy of (immunotherapy paired with chemotherapy, or radiotherapy) both preclinical clinical stages therapies utilizing various nanoparticles loaded anticancer agents, nucleic acids, immunotherapeutics, CRISPRs
Язык: Английский
Процитировано
7
International Journal of Pharmaceutics, Год журнала: 2025, Номер unknown, С. 125354 - 125354
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
1
Future Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 1 - 4
Опубликована: Март 14, 2025
Язык: Английский
Процитировано
1
Biomaterials Science, Год журнала: 2024, Номер 12(4), С. 896 - 906
Опубликована: Янв. 1, 2024
With the growing need for more effective tumour treatment, piezocatalytic therapy has emerged as a promising approach due to its distinctive capacities generate ROS through stress induction and regulate hypoxic state of TME. MOF-based piezocatalysts not only possess benefits piezocatalysis but also exhibit several advantages associated with MOFs, such tunable pore size, large specific surface area, good biocompatibility. Therefore, they are expected become powerful promoter therapy. This review elaborates on fundamental principles summarises recent advances in combination therapies tumours, generalising strategies constructing systems based MOFs. Finally, challenges confronted future opportunities design application MOF anticancer have been discussed.
Язык: Английский
Процитировано
6
Frontiers in Immunology, Год журнала: 2024, Номер 14
Опубликована: Янв. 12, 2024
Treatment of non-small-cell lung cancer (NSCLC) has entered the immunotherapy era, marked by significant survival improvements due to use immune checkpoint inhibitors (ICIs). However, owing factors, such as disease progression, long-term use, and side effects, some patients discontinue immunotherapy, resulting in limited subsequent treatment option a negative impact on their quality life. We have collected relevant data which reveal that ICI rechallenge may be an effective clinical strategy. many factors affect efficacy rechallenge, including patient characteristics, initial drugs, duration, efficacy, toxicity, effects. Additionally, effects mechanisms reversing drug resistance play crucial roles. Identifying suitable candidates, optimizing plans enhancing minimizing toxicity adverse rechallenges are pressing needs. Addressing these issues can provide guidance for better serve patients. This review focuses considerations strategies therapy NSCLC.
Язык: Английский
Процитировано
4
Materials Today Sustainability, Год журнала: 2024, Номер 27, С. 100865 - 100865
Опубликована: Май 27, 2024
Язык: Английский
Процитировано
4
Journal of Materials Chemistry B, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Current cancer treatments, including chemotherapy, surgery, and radiation, often present significant challenges such as severe side effects, drug resistance, damage to healthy tissues. To address these issues, we introduce a virus-inspired RNA mimicry approach, specifically through the development of uridine-rich nanoparticles (UNPs) synthesized using rolling circle transcription (RCT) technique. These UNPs are designed mimic poly-U tail sequences viral RNA, effectively engaging RIG-I-like receptors (RLRs) MDA5 LGP2 in cells. Activation leads upregulation pro-inflammatory cytokines initiation apoptosis, resulting targeted cell death. Importantly, this strategy overcomes limitations traditional therapies enhances effectiveness existing RIG-I stimulators, poly(I:C), which has exhibited toxicity clinical settings due delivery methods. Our vivo studies further demonstrate ability significantly reduce tumor growth without adverse highlighting their potential novel effective approach immunotherapy. This offers new therapeutic strategies that leverage body's innate antiviral mechanisms for treatment.
Язык: Английский
Процитировано
0